Cargando…

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

BACKGROUND: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yazıcı, Dilek, Yapıcı Eser, Hale, Kıyıcı, Sinem, Sancak, Seda, Sezer, Havva, Uygur, Melin, Yumuk, Volkan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028372/ https://www.ncbi.nlm.nih.gov/pubmed/36349778 http://dx.doi.org/10.1159/000526808

Ejemplares similares

Is obesity paradox valid for critically-ill COVID-19 patients with respiratory failure?
por: Sezer, Havva, et al.
Publicado: (2022)

Association between BRAF(V600E) mutation and the clinicopathological features in incidental papillary thyroid microcarcinoma: A single-center study in Turkish patients
por: Sezer, Havva, et al.
Publicado: (2020)

Out-of-Reference Range Thyroid-Stimulating Hormone Levels in Levothyroxine-Treated Primary Hypothyroid Patients: A Multicenter Observational Study
por: Yavuz, Dilek Gogas, et al.
Publicado: (2017)

The clinicopathologic characteristics of familial and sporadic papillary thyroid carcinoma in Turkish patients
por: SEZER, Havva, et al.
Publicado: (2020)

The Role of Obesity in Predicting the Clinical Outcomes of COVID-19
por: Sahin, Serdar, et al.
Publicado: (2021)

Status of Weight Change, Lifestyle Behaviors, Depression, Anxiety, and Diabetes Mellitus in a Cohort with Obesity during the COVID-19 Lockdown: Turk-Com Study Group
por: Yazıcı, Dilek, et al.
Publicado: (2022)

Obesity: A Gateway Disease with a Rising Prevalence
por: Frühbeck, Gema, et al.
Publicado: (2014)

Newer Vistas in Glucagon-Like Peptide-1 Analog Therapy - Marvels of Peptide Engineering
por: Jacob, Jubbin Jagan, et al.
Publicado: (2021)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission
por: Figueredo, Yaiseli, et al.
Publicado: (2023)

Erdheim-chester disease: Case report with testes involvement and review of literature
por: Sezer, Havva, et al.
Publicado: (2018)

Decreased psychiatric symptomatology after the onset of COVID-19 in a longitudinal college mental health study
por: Dogan, Asli Ercan, et al.
Publicado: (2022)

The frequency of acceptance of oral glucose tolerance test in Turkish pregnant women: A single tertiary center results
por: Sezer, Havva, et al.
Publicado: (2022)

Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
por: Anandhakrishnan, Ananthi, et al.
Publicado: (2016)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
por: Ebdrup, Bjørn H, et al.
Publicado: (2012)

Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications
por: Manandhar, Bikash, et al.
Publicado: (2014)

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome, Getnet, et al.
Publicado: (2020)

An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults
por: Zhu, Changzhen, et al.
Publicado: (2022)

Association of Excessive Daytime Sleepiness with the Zung Self-Rated Depression Subscales in Adults with Coronary Artery Disease and Obstructive Sleep Apnea
por: Celik, Yeliz, et al.
Publicado: (2021)

Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis
por: Vosoughi, Kia, et al.
Publicado: (2021)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
por: Zinman, Bernard, et al.
Publicado: (2009)

An EASO Position Statement on Multidisciplinary Obesity Management in Adults
por: Yumuk, Volkan, et al.
Publicado: (2014)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

Obesity Management in Europe: Current Status and Objectives for the Future
por: Uerlich, Magdalena F., et al.
Publicado: (2016)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

European Guidelines for Obesity Management in Adults
por: Yumuk, Volkan, et al.
Publicado: (2015)

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway
por: Liu, Jieyu, et al.
Publicado: (2013)

How Things Happen
por: Fried, Martin, et al.
Publicado: (2013)

Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol
por: Eren-Yazicioglu, Candan Yasemin, et al.
Publicado: (2021)

Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women
por: Topyildiz, Figen, et al.
Publicado: (2016)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer
por: He, Liang, et al.
Publicado: (2017)

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats
por: Zhang, Qian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dir98852q2r8mdi2i7dae5ekte